Skip to main content

Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”

The Original Article was published on 09 November 2020

The Original Research Article was published on 12 June 2020

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Manning R, et al. Comment on “Market exclusivity for drugs with multiple orphan approvals (1983–2017) and associated budget impact in the US”. Pharmacoeconomics. 2020. https://doi.org/10.1007/s40273-020-00975-7.

    Article  PubMed  Google Scholar 

  2. 2.

    Socal MP, Parasrampuria S, Anderson GF. Modifying the criteria for granting orphan drug market exclusivity. Value Health. 2020;23(11):1470–6. https://doi.org/10.1016/j.jval.2020.08.004.

    Article  PubMed  Google Scholar 

  3. 3.

    Padula WV, Parasraumpuria S, Socal M, Conti RM, Anderson GF. Market exclusivity for drugs with multiple orphan approvals (1983–2017) and the associated budget impact in the US. Pharmacoeconomics. 2020;38:1115–21. https://doi.org/10.1007/s40273-020-00934-2.

    Article  PubMed  Google Scholar 

  4. 4.

    Hakim A, Ross JS. Obstacles to the adoption of biosimilars for chronic diseases. J Am Med Assoc. 2017;317(21):2163–4.

    Article  Google Scholar 

  5. 5.

    Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273–86.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to William V. Padula.

Ethics declarations

Funding

The authors were supported by an unrestricted grant from Arnold Ventures Foundation to Johns Hopkins University to conduct this investigation.

Conflicts of Interest/Competing Interests

William V. Padula, Sonal Parasrampuria, Mariana P. Socal, Rena M. Conti, and Gerard F. Anderson have no conflicts of interest that are directly relevant to the content of this letter.

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Availability of Data and Material

Not applicable.

Code Availability

Not applicable.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Padula, W.V., Parasrampuria, S., Socal, M.P. et al. Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”. PharmacoEconomics 38, 1375–1376 (2020). https://doi.org/10.1007/s40273-020-00973-9

Download citation